Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2021
Number of items: 4.

2021

Heist, Rebecca Suk, Garon, Edward B., Tan, Daniel Shao-Weng, Groen, Harry J. M., Seto, Takashi, Smit, Egbert F., Zou, Mike R., Yang, Yiqun, Li, Ying, Chassot-Agostinho, Andrea and Wolf, Juergen (2021). Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Mueller, Karen Thudium, Grupp, Stephan A., Maude, Shannon L., Levine, John E., Pulsipher, Michael A., Boyer, Michael W., August, Keith J., Myers, G. Doug, Tam, Constantine S., Jaeger, Ulrich, Foley, Stephen Ronan, Borchmann, Peter, Schuster, Stephen J., Waller, Edmund K., Awasthi, Rakesh, Potthoff, Bernd, Warren, Andy, Waldron, Edward R., McBlane, Fraser, Chassot-Agostinho, Andrea and Laetsch, Theodore W. (2021). Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv., 5 (23). S. 4980 - 4992. AMSTERDAM: ELSEVIER. ISSN 2473-9537

Wolf, Juergen, Garon, Edward B., Groen, Harry J. M., Tan, Daniel Shao-Weng, Gilloteau, Isabelle, Le Mouhaer, Sylvie, Cai, Can, Chassot-Agostinho, Andrea, Reynolds, Maria, Odom, Dawn and Heist, Rebecca Suk (2021). Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Wolf, Juergen, Garon, Edward B., Groen, Harry J. M., Tan, Daniel Shao-Weng, Robeva, Anna, Le Mouhaer, Sylvie, Carbini, Mariana, Chassot-Agostinho, Andrea and Heist, Rebecca Suk (2021). Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

This list was generated on Fri Mar 29 02:55:12 2024 CET.